欧美成一级-欧美成在人线a免费-欧美传媒影-欧美大逼逼-欧美大成色www永久网站婷-欧美大胆a级视频

Cell Therapy
Universal Cell Platform
Quikin CAR-T Platform
Enhanced T Cell Platforms

Universal Cell Platform


Universal Cell Platform (TyUCell?) refers to the use of gene editing technology to transform allogeneic immune cells to eliminate immune rejection. On the basis of ensuring the safety and effectiveness of cell products, it realizes the generalization of immune cell therapy products. Tyucell cell products have the advantages of low cost, wide application range, short production cycle, stable preparation process and good therapeutic effect. The platform can be used for clinical treatment after a large number of expansion of cells from healthy donors. At the same time, it can realize the large-scale and batch production of cell products, significantly reduce the production cost, shorten the waiting time of patients, and provide modern cell therapy products that meet the urgent needs of clinic.


The development of the era of gene therapy

In 2023, the world's first all human targeted BCMA CAR-T therapy "FUCASO" (Equecabtagene Autoleucel) was approved for sale in China for the treatment of recurrent or refractory multiple myeloma (R/R MM)
In 2022, Cilta cel, the first CAR-T cell therapy for the treatment of r/r MM in China, was approved by the FDA for marketing
In 2021, China's first CAR-T product, Aquilensai injection, was approved for marketing by the Chinese NMPA for post-treatment relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
In 2020，CRISPR/Cas9 gene editing technology wins Nobel Prize in Chemistry
In June 2019, zynteglo, the world's first gene therapy drug ,was approved for marketing by the EU EMA for the treatment of thalassemia
In May 2019, Zolgensma, the world's first gene therapy drug,was approved for marketing by the FDA for the treatment of SMA
In 2018, the first CRISPR/Cas9-based in vivo gene therapy clinical trial (EDIT-101) was approved by the FDA for the treatment of Leber Congenital Amaurosis Type 10 (LCA)
In 2017, Kymriah, the world's first CAR-T product, received FDA approval to market for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL)
In 2016, the first generation of single-base editors were developed
In November 2013, the third generation gene editing technology CRISPR/Cas9 (clustered regularly spaced short palindromic repeats) was introduced
In 2012, Glybera, the world's first AAV gene therapy drug, was approved for marketing by the EU EMA for the treatment of lipoprotein lipase deficiency (LPLD)
In 2010, TALENs (transcription activation-like effector nucleases), a second-generation gene editing technology, was introduced
In 2003, Gendicine, the world's first gene therapy drug, was approved for marketing by the NMPA in China for the treatment of head and neck squamous cell carcinoma (HNSCC)
In 2001, the first generation of gene editing technology ZFNs (zinc finger nucleases) was introduced
In 1990, the world's first clinical trial of gene therapy was approved by the FDA for the treatment of adenosine deaminase deficiency (ADA-SCID)
Back to top
主站蜘蛛池模板： 亚洲第一福利网站在线观看 | 欧美日韩国产一区二区三区欧 | 99精品视频在线观看免费播放 | 国产高清一区二区三区 | 午夜成人污动漫在线观看 | 欧美成人观看免费完全 | 午夜影视网站 | 国产福利电影一区二区三区 | 能在线观看的手机黄页 | 久久精品久久精品中文字幕 | 国产精品福利久久电影 | 欧美国产日韩久久mv | 2025国产精品福利在线观看 | 亚洲九九 | 免费看啪啪人a片aaa片 | 麻豆传媒 | 国产老人粗话xxx免费视频 | 亚洲国产精品+制服丝袜 | 日韩中文字幕六区 | 国产精品高清视亚洲一区二区 | 国产妇女性爽视频免费 | 亚洲无码一区二区三区 | 国产伦久久久久久久 | 一本大道香蕉高清久久 | 爱福利极品盛宴色一区 | 日日av拍夜夜添久久免费 | 亚洲精品白浆高清久久久 | 日本五级床片午夜视频 | 亚洲伦理一区二 | 成年福利片在线观看 | 性生大片免费观看网站 | 国产传媒日韩精品无码视频 | 色综合色狠狠天天综合桃花影视 | 亚洲天堂av电影在线观看 | 日韩精品专区在线影院重磅 | 国产精品国产高清国产v | 免费精品国产日韩热久久 | 国产伦精品一区二区三区妓女 | 久久只有这里的精 | 日韩精品一区二区三区 | 免费成人激情视频 |